- Home
- FLNC vs ATAI Comparison
FLNC vs ATAI Comparison
Compare FLNC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- ATAI
- Stock Information
- Founded
- FLNC 2018
- ATAI 2018
- Country
- FLNC United States
- ATAI Netherlands
- Employees
- FLNC N/A
- ATAI N/A
- Industry
- FLNC Industrial Machinery/Components
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- ATAI Health Care
- Exchange
- FLNC Nasdaq
- ATAI Nasdaq
- Market Cap
- FLNC 974.7M
- ATAI 1.1B
- IPO Year
- FLNC 2021
- ATAI 2021
- Fundamental
- Price
- FLNC $20.80
- ATAI $5.35
- Analyst Decision
- FLNC Hold
- ATAI Strong Buy
- Analyst Count
- FLNC 19
- ATAI 5
- Target Price
- FLNC $9.86
- ATAI $14.00
- AVG Volume (30 Days)
- FLNC 8.7M
- ATAI 7.2M
- Earning Date
- FLNC 11-24-2025
- ATAI 11-14-2025
- Dividend Yield
- FLNC N/A
- ATAI N/A
- EPS Growth
- FLNC N/A
- ATAI N/A
- EPS
- FLNC N/A
- ATAI N/A
- Revenue
- FLNC $2,449,087,000.00
- ATAI $2,309,000.00
- Revenue This Year
- FLNC N/A
- ATAI $736.04
- Revenue Next Year
- FLNC $20.52
- ATAI N/A
- P/E Ratio
- FLNC N/A
- ATAI N/A
- Revenue Growth
- FLNC 14.26
- ATAI 510.85
- 52 Week Low
- FLNC $3.46
- ATAI $1.05
- 52 Week High
- FLNC $24.00
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- FLNC 64.46
- ATAI 46.45
- Support Level
- FLNC $17.90
- ATAI $5.50
- Resistance Level
- FLNC $20.18
- ATAI $5.91
- Average True Range (ATR)
- FLNC 1.97
- ATAI 0.45
- MACD
- FLNC 0.09
- ATAI -0.08
- Stochastic Oscillator
- FLNC 79.83
- ATAI 5.88
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.